Skip to main content
SpringerLink
Log in

Hepatologie — Teil 6: Hepatitis C

HCV — Eine Erkrankung auf dem — Weg zur Eradikation?

  • fortbildung
  • Published:
Gastro-News Aims and scope

Kaum eine andere Erkrankung hat in den letzten Jahren für so viel öffentliches Interesse gesorgt wie die Hepatitis-C-Virus-Infektion und ihre neuen Therapieoptionen, zu gleichen Teilen wegen ihrer sensationellen Heilungserfolge, aber auch wegen ihrer in der ersten Phase „sensationellen“ Preise. Mittlerweile ist aber vielfach belegt worden, dass die Behandlung der chronischen Hepatitis C in jedem Fall nicht nur Komplikationen der Leberzirrhose verhindert, sondern kosteneffektiv und langfristig sogar kostensparend ist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3
4
5

Literatur

  1. Wedemeyer H et al. Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. Liv Int 2017; 37:1468–14752

    Article  CAS  Google Scholar 

  2. Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol 2018;5:1178–1187

    Article  Google Scholar 

  3. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 4: 401–412.

    Article  Google Scholar 

  4. Global Hepatitis Report 2017; http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

  5. Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat 2018 Nov;25 Suppl 3:6–14

    Article  PubMed  Google Scholar 

  6. Antidhilfe.de nach Sarrazin C et al. Z Gastroenterol 2010, 48: 289–351

    Article  CAS  PubMed  Google Scholar 

  7. Epidemiologisches Bulletin, Ausgabe 29/2018, S. 275

  8. Zeuzem et al. Dtsch Arztebl Int 2017;114(1-2):11–21

    PubMed  PubMed Central  Google Scholar 

  9. Sarrazin C, Zimmermann T, Berg T, Neumann UP, Schirmacher P, Schmidt H et al. S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion“. Z Gastroenterol 2018; 56:756–838

    Article  PubMed  Google Scholar 

  10. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; https://doi.org/10.1016/j.jhep.2018.03.026

    Google Scholar 

  11. Höner zu Siederdissen C, Buggisch P, Böker KHW, Schott E, Klinker H, Pathil A et al. Treatment of Hepatitis C genotype 1 infection in Germany — effectiveness and safety of antiviral treatment in a real world setting. UEG Journal 2018;6:213–224

    PubMed  Google Scholar 

  12. Tacke F, Günther R, Buggisch P, Klinker H, Schober A, John C et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int. 2017;37:205–211

    Article  CAS  PubMed  Google Scholar 

  13. Cornberg M, Petersen J, Schober A, Mauss S, Böker KHW, Link R et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. AP&T 2017;45:688–700

    CAS  Google Scholar 

  14. Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M et al. Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients: Results from the German Hepatitis C-Registry. Drugs & Aging 2018;35:843–857

    Article  CAS  Google Scholar 

  15. Bischoff J, Mauss, Cordes D, Lutz T, Scholten S, Moll A et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Medicine 2018;19:299–307

    Article  CAS  PubMed  Google Scholar 

  16. Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hep 2018;68:663–671

    Article  CAS  Google Scholar 

  17. Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D et al. Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. Journal of Hepatology 2018;69:982–984

    Article  PubMed  Google Scholar 

  18. Wedemeyer H. Dtsch Arztebl 2018;115:27–28

    Google Scholar 

  19. Reese P et al.: Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial, Ann Intern Med. 2018;169(5):273–281

    Article  PubMed  Google Scholar 

  20. Willuweit K et al.: Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation. Minerva Gastroenterol Dietol. 2017 Mar;63(1):55–61

    PubMed  Google Scholar 

  21. Polaris Observatory HCV Collaborators: Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161–76

    Article  Google Scholar 

  22. Christensen S, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? Addiction 2018;113:868–882

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Deutschland

    Gudrun Hilgard &  Heiner Wedemeyer

Authors
  1. Gudrun Hilgard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heiner Wedemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gudrun Hilgard.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hilgard, G., Wedemeyer, H. HCV — Eine Erkrankung auf dem — Weg zur Eradikation?. Gastro-News 5, 48–52 (2018). https://doi.org/10.1007/s15036-018-0506-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-018-0506-z

Search

Navigation